Cannabinoid Receptor CB2 Is a Potential Prognostic Biomarker in NSCLC
Overexpression of cannabinoid receptor CB2 may be a prognostic biomarker for NSCLC adenocarcinomas.
Diagnosis & Disease Information
First-Line Nivolumab Plus Chemotherapy Improves Survival in Gastric, Gastroesophageal Junction, and Esophageal Cancers
Nivolumab plus chemotherapy prolonged survival of patients with advanced gastric, gastroesophageal junction, and esophageal cancers compared with chemotherapy.
Promising Findings for Palbociclib Plus Fulvestrant in the Frontline Setting for HR-Positive, HER2-Negative MBC
Currently, fulvestrant plus palbociclib is approved by the FDA in the metastatic breast cancer setting only following disease progression on endocrine therapy.
Opposition to a European Patent for CAR-T Therapy: A Mechanism to Control High Drug Prices?
The nongovernmental organizations argued that patents for this CAR-T should never have been granted in the first place because the underlying technology is not novel.
Pembrolizumab Plus Chemotherapy Prolonged Survival in Esophageal or EGJ Cancers
First-line pembrolizumab plus chemotherapy prolonged survival among patients with advanced esophageal or esophagogastric junction cancer.
Tracking Symptoms and Outcomes in Real-World Patients Exhibiting Rheumatic irAEs
Different patterns of rheumatic symptoms were observed in patients with rheumatic irAEs.
Disparities in Access to Clinical Trials in Europe
A new study examines the differences in access to novel therapies for European patients with cancer compared with patients in other geographic regions.
Addition of a CDK4/6 Inhibitor to Adjuvant Endocrine Therapy Improves Outcomes in HR+, HER2-, High-Risk Early Breast Cancer
This phase 3 study compared endocrine therapy with or without abemaciclib in patients with high-risk, early-stage, hormone receptor-positive, HER2-negative breast cancer.
Two-Drug Combo Superior to Sunitinib as First-Line Therapy for Advanced RCC
Compared with sunitinib alone, nivolumab plus cabozantinib therapy was associated with a 49% decreased risk for progression and 40% decreased risk for death.
Radiologic PFS Benefit Observed for Addition of AKT Inhibitor to Abiraterone in Metastatic CRPC
Loss of the tumor suppressor PTEN, a negative prognostic factor in metastatic CRPC, is associated with dysregulation of the PI3K–AKT–mTOR pathway.
- Loading...
Loading...
Next post in ESMO Virtual Congress 2020
Loading... 
Loading...